These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 16964677)

  • 21. Recommendations for the treatment of chronic hepatitis C infection in children.
    Mirza R; Memon I; Cheema HA; Ali S; Thobani S; Shah U
    J Pak Med Assoc; 2007 Aug; 57(8):419-20. PubMed ID: 17902528
    [No Abstract]   [Full Text] [Related]  

  • 22. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review.
    Andrade LJ; Atta AM; D'Almeida Junior A; Paraná R
    Braz J Infect Dis; 2008 Apr; 12(2):144-8. PubMed ID: 18641852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.
    Gehring S; Kullmer U; Koeppelmann S; Gerner P; Wintermeyer P; Wirth S
    World J Gastroenterol; 2006 Sep; 12(36):5787-92. PubMed ID: 17007043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuropsychiatric disorders in HCV-infected people--own observations].
    Czarnecki M; Inglot M; Małyszczak K; Rymer W; Jańczak G; Pawłowski T; Gładysz A
    Przegl Epidemiol; 2005; 59(2):431-8. PubMed ID: 16190551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hypothyroid myopathy caused by interferon-alpha therapy for chronic hepatitis C].
    Nagane Y; Utsugisawa K; Kizawa H; Kondoh R; Terayama Y
    Rinsho Shinkeigaku; 2005 Jun; 45(6):441-4. PubMed ID: 16022470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose ribavirin has been effective in the treatment of incapacitating muco-cutaneous extrahepatic manifestations in patients with hepatitis C with contraindication or no access for approved antiviral treatment.
    Esmail ES; Asal FH; Yussif M; Elfert AA
    Arab J Gastroenterol; 2015; 16(3-4):125-8. PubMed ID: 26526507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?
    Mazziotti G; Sorvillo F; Carbone A; Cioffi M; Morisco F; Carella C
    J Intern Med; 2002 Oct; 252(4):377-8; author reply 379. PubMed ID: 12366611
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
    Vogel W
    Wien Klin Wochenschr; 2004 Aug; 116(15-16):508-10. PubMed ID: 15471176
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy.
    Uto H; Matsuoka H; Murata M; Okamoto T; Miyata Y; Hori T; Ido A; Hirono S; Hayashi K; Tsubouchi H
    Diabetes Res Clin Pract; 2000 Aug; 49(2-3):101-6. PubMed ID: 10963820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].
    Obołończyk L; Obołończyk L; Siekierska-Hellmann M; Sworczak K
    Postepy Hig Med Dosw (Online); 2007 Jun; 62():309-21. PubMed ID: 18583950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
    Kawazoe T; Araki M; Lin Y; Ogawa M; Okamoto T; Yamamura T; Wakakura M; Murata M
    Intern Med; 2012; 51(18):2625-9. PubMed ID: 22989839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy.
    Kose S; Gozaydin A; Akkoclu G; Ece G
    J Infect Dev Ctries; 2012 Apr; 6(4):364-8. PubMed ID: 22505448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon therapy in hepatitis C leading to chronic type 1 diabetes.
    Zornitzki T; Malnick S; Lysyy L; Knobler H
    World J Gastroenterol; 2015 Jan; 21(1):233-9. PubMed ID: 25574096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Underlying pathways for interferon risk to type II diabetes mellitus.
    Abdel-Hamid N; Jubori TA; Farhan A; Mahrous M; Gouri A; Awad E; Breuss J
    Curr Diabetes Rev; 2013 Nov; 9(6):472-7. PubMed ID: 24111619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type 1 diabetes and interferon therapy: a nationwide survey in Japan.
    Nakamura K; Kawasaki E; Imagawa A; Awata T; Ikegami H; Uchigata Y; Kobayashi T; Shimada A; Nakanishi K; Makino H; Maruyama T; Hanafusa T;
    Diabetes Care; 2011 Sep; 34(9):2084-9. PubMed ID: 21775762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection.
    Panfilio S; D'Urso P; Annechini G; D'Elia GM; De Angelis F; Stefanizzi C; Pulsoni A
    Leuk Res Rep; 2013; 2(1):39-40. PubMed ID: 24371776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autoimmune diabetes after treatment with interferon-alpha].
    Mathieu E; Fain O; Sitbon M; Thomas M
    Presse Med; 1995 Jan; 24(4):238. PubMed ID: 7899374
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-rods/rings autoantibodies in a patient with pancreatic injury.
    Katayama S; Kubota T; Takahashi H; Shiwaku H
    Autoimmun Rev; 2022 Jan; 21(1):102922. PubMed ID: 34418537
    [No Abstract]   [Full Text] [Related]  

  • 39. [The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type].
    Jasonek J; Kacprzak-Bergman I; Zaleska I
    Przegl Epidemiol; 2006; 60(2):259-63. PubMed ID: 16964677
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.